<code id='85761CB975'></code><style id='85761CB975'></style>
    • <acronym id='85761CB975'></acronym>
      <center id='85761CB975'><center id='85761CB975'><tfoot id='85761CB975'></tfoot></center><abbr id='85761CB975'><dir id='85761CB975'><tfoot id='85761CB975'></tfoot><noframes id='85761CB975'>

    • <optgroup id='85761CB975'><strike id='85761CB975'><sup id='85761CB975'></sup></strike><code id='85761CB975'></code></optgroup>
        1. <b id='85761CB975'><label id='85761CB975'><select id='85761CB975'><dt id='85761CB975'><span id='85761CB975'></span></dt></select></label></b><u id='85761CB975'></u>
          <i id='85761CB975'><strike id='85761CB975'><tt id='85761CB975'><pre id='85761CB975'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:634
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          At flashy new research hub, AstraZeneca lays out ambitious growth goals
          At flashy new research hub, AstraZeneca lays out ambitious growth goals

          PascalSoriothasservedasCEOofAstraZenecasince2012.WinMcNamee/GettyImagesCAMBRIDGE,England—Onabitofaro

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Amylyx ALS drug failure raises questions and concerns

          Relyvrio,anALSdrugmadebyAmylyxPharmaceuticals,failedtobeatplaceboinakeyclinicaltrial.AmylyxPharmaceu